Site icon Market Globalist

NeuroMetrix Inc. (NURO) stock plunged during pre-market. Let’s find out why?

NeuroMetrix Inc. (NASDAQ: NURO) stock gained by 18.89% at last close while the NURO stock price losses by -4.12% in the pre-market trading session. NeuroMetrix is a technology-driven business that develops and markets non-invasive medical devices for the management and therapy of pain and neurological diseases throughout the world.

>> 7 Top Picks for the Post-Pandemic Economy << 

Financial Results

NeuroMetrix announced its second-quarter 2021 financial results. Given below is the summary:

Read More

Shai N. Gozani, President and CEO of NeuroMetrix commented,

In both the DPNCheck and Quell business lines, they made steady progress. NURO believes that they are establishing the foundation for long-term top-line development. In June, it was very satisfying to present the Quell fibromyalgia findings to international pain medicine specialists and to earn FDA Breakthrough Device Designation. They’re excited to see this initiative progress toward a commercial launch in 2022.

Exit mobile version